Combination Adriamycin and radiation therapy in gynecologic cancers.
Anthracyclic antibiotics, of which Adriamycin is representative, have the ability to bind to cellular DNA and thereby interfere with the X-ray repair process. When radiation survival curves of tissue cultures were studied, increased cell-killing was noted in those cultures with Adriamycin over those without the drug. The mechanism by which this occurs may be related to a reduced rate of DNA strand break rejoining, as demonstrated by use of alkaline sucrose gradient techniques. A preliminary clinical Phase I study, in which patients with advanced gynecologic malignancy were treated by simultaneous Adriamycin and X radiation, suggests that combined therapy is well-tolerated, and that such combinations may prove useful in selected patients.
D002470:Cell Survival; D004247:DNA / Q000528:radiation effects; D004260:DNA Repair / Q000187:drug effects; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D066298:In Vitro Techniques; D010051:Ovarian Neoplasms; D011878:Radiotherapy; D002583:Uterine Cervical Neoplasms
D004317:Doxorubicin; D004247:DNA